Pyxis Oncology shareholders elect three directors at annual meeting

Pyxis Oncology , Inc. (NASDAQ:PYXS), a Boston-based pharmaceutical company currently trading at $1.14 per share, announced the voting results from its Annual Meeting of Stockholders held Wednesday in a virtual format. The company’s stock has declined nearly 11% over the past week, though InvestingPro analysis shows it maintains a strong balance sheet with more cash than debt.

According to an SEC filing, stockholders elected three Class I directors to serve until the company’s 2028 Annual Meeting. Dr. Santhosh Palani received 22,056,449 votes in favor and 7,314,363 votes withheld. Mr. Darren Cline garnered 22,028,914 votes in favor and 7,341,898 votes withheld. Dr. Rachel Humphrey secured 21,357,102 votes in favor and 8,013,710 votes withheld.

Stockholders also ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal received overwhelming support with 43,733,259 votes in favor, 233,563 votes against, and 29,628 abstentions.

The meeting had a quorum with 43,996,450 shares represented, out of 61,947,665 total shares outstanding and entitled to vote as of the April 21, 2025 record date.

Pyxis Oncology is a pharmaceutical company based in Boston, Massachusetts. The company filed the voting results with the Securities and Exchange Commission on June 18, 2025.

In other recent news, Pyxis Oncology announced promising preclinical data for its leading drug candidate, micvotabart pelidotin (MICVO), at the American Association for Cancer Research Annual Meeting 2025. The preclinical studies demonstrated MICVO’s potential to disrupt tumor structure and induce immunogenic cell death, showing broad anti-tumor activity across ten solid tumor indications. Notably, MICVO has received Fast Track Designation from the U.S. Food and Drug Administration for treating recurrent and metastatic head and neck squamous cell carcinoma and is currently in Phase 1 clinical trials. In another development, Jefferies lowered Pyxis Oncology’s price target from $12.00 to $6.00 but maintained a Buy rating on the stock. Jefferies noted the company’s strong cash position, with $146 million expected to support operations into the second half of 2026. The firm highlighted upcoming significant data events for MICVO, including its use as a monotherapy and in combination with pembrolizumab. Jefferies also pointed to the competitive landscape, with data from competitors expected to inform Pyxis Oncology’s strategic decisions. Despite the reduced price target, Jefferies remains optimistic about Pyxis Oncology’s prospects due to its pipeline and financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.